Navigation Links
Mylan Receives Approval for Generic Version of Xalatan® Ophthalmic Solution
Date:4/4/2011

PITTSBURGH, April 4, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Latanoprost Ophthalmic Solution, 0.005%, the generic version of Pharmacia and Upjohn's Xalatan® Ophthalmic Solution, an eyedrop that lowers pressure in the eye.  

Mylan President Heather Bresch said: "We are very pleased to introduce this product to the market as it represents Mylan's first ophthalmic solution. This signifies a new internal development capability for the company, and we currently have in development a number of additional products in this important category."  

Latanoprost Ophthalmic Solution had U.S. sales of approximately $711 million for the 12 months ending Dec. 31, 2010, according to IMS Health. Mylan is shipping this product immediately.

Currently, Mylan has 168 ANDAs pending FDA approval representing $98.7 billion in annual sales, according to IMS Health. Forty-eight of these pending ANDAs are potential first-to-file opportunities, representing $25.9 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Announces Exclusive Distribution Partnership with Humeca to Expand Burn and Wound Care Portfolio
2. Moodys Upgrades Mylan
3. Mylan Confirms First-to-File Patent Challenge Relating to Vivelle-Dot®
4. Mylan Receives Approval for Generic Version of Neurontin® Capsules
5. Mylan Launches First Generic Version of Vfend® Tablets
6. Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets
7. Mylans Matrix Obtains License for Promising HIV/AIDS Treatment
8. Mylan Announces Lipitor® Settlement Agreement
9. Mylan Announces Caduet® Settlement Agreement
10. Mylans Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
11. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Jan. 17, 2017 Secretary of Health Dr. ... Secretary Gary Tennis are warning Pennsylvanians of ... recent overdose deaths from the drug in ... intended to sedate large animals and is not meant ... comes into contact with it," Secretary Murphy said. "It,s ...
(Date:1/17/2017)... Jan 17, 2017 Research and Markets ... Materials: 2017 - 2024" report to their offering. ... This new report revisits ... report that was issued in May of 2015. Self-healing is an ... our previous analysis we projected a market potential of $2.7 billion ...
(Date:1/17/2017)... The Global Nebulizers Market is poised to ... next decade to reach approximately $1698.68 million by 2025. ... witnessing include rapidly growing demand in emerging regions, increasing ... products and online marketing strategies by key players. ... into pneumatic nebulizers, ultrasonic nebulizers and mesh nebulizers. Pneumatic ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... Visually learn ... one doctor-recommended OTC antiperspirant, Certain Dri. , Excessive sweating and hyperhidrosis are common ... created this infographic to explain the seven types of hyperhidrosis. This visual creates ...
(Date:1/18/2017)... ... January 18, 2017 , ... The V Foundation for Cancer Research, ... official endurance training and fundraising team, to compete in the Boston Marathon on April ... to finish the world’s oldest annual marathon to join Team V and support the ...
(Date:1/18/2017)... Park, KS (PRWEB) , ... January 18, 2017 ... ... managed firm offering asset protection and financial planning services to families and business ... a charity event aimed at supporting children with developmental disabilities. , The Lakemary ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael J. Hennessy Associates, Inc., ... Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael J. Hennessy, ... biosimilars through thought leader interaction in, live video and interactive digital platforms. , ...
(Date:1/18/2017)... VA (PRWEB) , ... January 18, 2017 , ... Floundering ... American Heart Month and the perfect time for a reset. The U.S. Apple Association ... studies to combat many of the factors that contribute to heart disease. , The ...
Breaking Medicine News(10 mins):